HUTCHMED (China) (HCM) Return on Capital Employed (2019 - 2021)

HUTCHMED (China) (HCM) posted quarterly Return on Capital Employed of 92.3% for Q4 2021, up 54.2% quarter-over-quarter from 59.85% in Q1 2021.

HUTCHMED (China) (HCM) Return on Capital Employed (2019 - 2021) Analysis & Trends

HUTCHMED (China) (HCM) has reported Return on Capital Employed for 3 consecutive years, with 92.3% the latest figure, recorded in Q4 2021.

In Q4 2021, Return on Capital Employed changed N/A year-over-year to 92.3%; the TTM figure through Dec 2021 stood at 92.3% (changed N/A YoY), while the FY2025 annual figure was 0.0%, changed N/A from the prior year.
Return on Capital Employed grew to 92.3% in Q4 2021 per HCM's latest filing, from 59.85% in the prior quarter.
Across five years, Return on Capital Employed topped out at 92.3% in Q4 2021 and bottomed at 72.86% in Q3 2019.
Historically, Return on Capital Employed has averaged 1.9% across 3 years, with a median of 7.27% in 2019.
On a YoY basis, Return on Capital Employed climbed as much as 9437 bps in 2020 and fell as far as 9437 bps in 2020.
HUTCHMED (China)'s Return on Capital Employed stood at 45.75% in 2019, then soared by 189 bps to 40.68% in 2020, then jumped by 127 bps to 92.3% in 2021.
Business Quant data shows HCM's Return on Capital Employed at 92.3% in Q4 2021, 59.85% in Q1 2021, and 40.68% in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	6.60%
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	17.16%
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	6.07%
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	22.04%
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	-0.29%
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	18.67%
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	5.52%
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	-
10	HUTCHMED (China)	2.18 Bn	2.18 Bn	-	-

Download Data